TAIGEN
太景醫藥研發控股股份有限公司
TAIGEN is a Taiwan TPEx-listed biotechnology company; its most advanced asset is TG-1000 (China marketing authorization approved, Uncomplicated influenza A and B in adults and adolescents aged 12 years and older), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| TG-1000 | — | China marketing authorization approved | Uncomplicated influenza A and B in adults and adolescents aged 12 years and older | China | 2025-12-11 | Company disclosure |
| ISM-4808 | HIF-PHD | Phase 1; first participant dosed | Anemia associated with chronic kidney disease | — | 2026-03-03 | Company disclosure |
| TG-2349 | — | Phase 3; completed | Chronic Hepatics C Virus (HCV) Genotype 1; Non-Cirrhotic; Cirrhosis; Treatment naïve | China | 2021-02-04 | Trial registry |
Key events
- TG-1000: Phase 3 trial authorized
- ISM-4808: Phase 1; first participant dosed
- TG-1000: China marketing authorization approved
Related Drugnews articles
No related articles in this language.